Review
Immunology
Xidan Gao, Hongshu Sui, Shang Zhao, Xingmei Gao, Yanping Su, Peng Qu
Summary: MDSCs, a heterogeneous population of immature myeloid cells accumulating in tumor-bearing hosts, play a critical role in promoting tumor immune escape. Therapeutic strategies targeting MDSCs have shown potential in enhancing the efficacy of tumor immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Saisha A. Nalawade, Paul Shafer, Pradip Bajgain, Mary K. McKenna, Arushana Ali, Lauren Kelly, Jarrett Joubert, Stephen Gottschalk, Norihiro Watanabe, Ann Leen, Robin Parihar, Juan Fernando Vera Valdes, Valentina Hoyos
Summary: The study demonstrates that CAR T cells coexpressing the TR2.4-1BB receptor exhibit superior antitumor potential against breast tumors containing immunosuppressive and tumor-promoting MDSCs, leading to TME remodeling and improved T cell proliferation at the tumor site.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Yang Zhao, Junfeng Du, Xiaofei Shen
Summary: Myeloid-derived suppressor cells (MDSCs) are a major negative regulator in tumor microenvironment (TME) by inhibiting immune response and promoting immunosuppression. This review focuses on the features of MDSCs in TME and potential targets for tumor immunotherapy. Therapies aiming to reprogram TME, prevent MDSC immunosuppression, promote MDSC differentiation, and impact MDSC recruitment and abundance in tumor site are discussed. Combinatorial strategies to improve clinical efficacy and outcomes of cancer patients through better understanding of MDSCs generation and suppression in TME are also summarized.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Shweta Joshi, Andrew Sharabi
Summary: This review discusses the role of MDSCs in tumor growth, their interaction with NK cells, and the impact on NK cell-based immunotherapies, presenting strategies to enhance NK cell cytotoxicity.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Immunology
Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman
Summary: MDSC play a key role in the immunosuppressive microenvironment of hematological cancers, associated with tumor cell survival and drug resistance. Despite intensive studies on the phenotype, function, and prognostic value of MDSC in hematological cancers, therapeutic targeting of this cell population remains challenging.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Dermatology
Pengfei Sun, Zhensheng Hu, Bo Pan, Xiaosheng Lu
Summary: Keloid is a common disease in plastic surgery, with poor treatment effects using methods such as drug injection, surgical resection, cryotherapy, and laser treatment. The discovery of TRAIL in 1995 has led to its potential use in targeting tumors, and recent research has shown its potential in treating keloids by inducing fibroblast apoptosis through TRAI binding to its receptor.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2021)
Article
Immunology
Vipul K. Singh, Arshad Khan, Yitian Xu, Sunny Mai, Licheng Zhang, Abhishek Mishra, Blanca I. Restrepo, Ping-Ying Pan, Shu-Hsia Chen, Chinnaswamy Jagannath
Summary: This study demonstrates that antagonism of LILRB2 can reprogram human MDSCs into M1 macrophages, leading to enhanced killing of Mycobacterium tuberculosis. This finding provides a potential avenue for targeting MDSCs to eradicate Mtb.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Xueyan Li, Xue Deng, Xiaoqi Luo, Jiahui Zhong, Hui Wu, Siru Chen, Jiayi Chen, Xuhui Huang, Changjun Wang
Summary: Alcohol consumption can inhibit the growth of liver cancer by regulating the immunosuppressive microenvironment, specifically through the downregulation of myeloid-derived suppressor cells (MDSCs) and the increase of CD4+ and CD8+ T cells.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Immunology
Juan Cruz Gamba, Carolina Roldan, Estefania Prochetto, Giuliana Lupi, Ivan Bontempi, Carolina Veronica Poncini, Monica Vermeulen, Ana Rosa Perez, Ivan Marcipar, Gabriel Cabrera
Summary: The study demonstrates the significant influence of MDSCs on the immune response during T. cruzi infection, even in vaccinated mice, impacting various immune cell populations. Targeting MDSCs may be an effective tool in vaccine design against T. cruzi and potentially other conditions characterized by immune system subversion.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Multidisciplinary Sciences
Amanda A. van Vliet, Ella Peters, Denise Vodegel, Danielle Steenmans, Monica Raimo, Susan Gibbs, Tanja D. de Gruijl, Adil D. Duru, Jan Spanholtz, Anna-Maria Georgoudaki
Summary: UCB CD34(+) progenitor cell-derived NK cells showed efficient cytotoxicity against melanoma cells, and this performance was consistent among different UCB donors and correlated with the levels of IFNg, TNF, perforin and granzyme B. Perforin and granzyme B levels predicted NK cell cytotoxic capacity. The involvement of multiple activating receptors, especially TRAIL, was identified as the mode of action for the synergistic cytotoxic NK cell activity.
Article
Immunology
Xueyan Li, Xiaoqi Luo, Siru Chen, Jiayi Chen, Xue Deng, Jiahui Zhong, Hui Wu, Xuhui Huang, Changjun Wang
Summary: Hepatocellular carcinoma is characterized by high infiltration of myeloid-derived suppressor cells (MDSCs), which are key drivers of maintaining the immunosuppressive tumor microenvironment. All-trans retinoic acid (ATRA) can differentiate MDSCs into mature myeloid cells, but its effect on liver cancer growth inhibition is unknown.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Yani Berckmans, Yannick Hoffert, Ann Vankerckhoven, Erwin Dreesen, An Coosemans
Summary: The lethality of ovarian cancer remains high and current treatment strategies often fail due to therapy resistance. Immunotherapy trials against ovarian cancer have also been unsuccessful so far. This review focuses on drug-repurposing to target myeloid-derived suppressor cells (MDSC) in ovarian cancer. A literature search identified seventeen repurposable compounds, of which four (lurbinectedin, metformin, celecoxib, and 5-azacytidine) were considered the most promising candidates with preclinical effects on MDSC and clinical evidence in ovarian cancer.
Article
Surgery
Sha Zhu, Yunuo Zhao, Yuxin Quan, Xuelei Ma
Summary: MDSCs play a crucial role in tumor progression under chronic stress settings, and their potential involvement in post-surgical tumor development has not been fully explored. Further research is needed to validate the hypothesis that targeting MDSCs could prevent post-surgical recurrence and metastasis, ultimately offering better long-term survival for cancer patients.
FRONTIERS IN SURGERY
(2021)
Review
Immunology
Xueyan Li, Jiahui Zhong, Xue Deng, Xuan Guo, Yantong Lu, Juze Lin, Xuhui Huang, Changjun Wang
Summary: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that are activated under pathological conditions, such as cancer, or mature myeloid cells that are converted into immune-suppressive cells via tumor-derived exosomes. They play a potent role in supporting tumor processes through various mechanisms, including inducing immune checkpoint blockade therapy resistance and promoting tumor progression. Targeting MDSCs is considered a potential therapeutic strategy to enhance the antitumor efficacy of immune checkpoint blockade therapy in multiple cancer cases.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Carlos Jimenez-Cortegana, Natalia Palazon-Carrion, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Fernando Carnicero-Gonzalez, Eduardo Rios-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodriguez-Garcia, Ruben Fernandez-Alvarez, Antonio Rueda Dominguez, Maria Casanova-Espinosa, Natividad Martinez-Banaclocha, Josep Guma-Padro, Jose Gomez-Codina, Jorge Labrador, Antonio Salar-Silvestre, Delvys Rodriguez-Abreu, Laura Galvez-Carvajal, Mariano Provencio, Margarita Sanchez-Beato, Maria Guirado-Risueno, Pablo Espejo-Garcia, Marylene Lejeune, Tomas Alvaro, Victor Sanchez-Margalet, Luis de la Cruz-Merino
Summary: In this study, MDSC and Treg levels were found to be increased in all patients with relapsed/refractory diffuse large B-cell lymphoma compared to healthy controls, and decreased after treatment only in patients with longer overall survival. Additionally, activated T lymphocytes increased after therapy in patients with better overall survival, suggesting a possible role of MDSCs and Treg cells in immunosuppression and as potential therapeutic targets in DLBCL.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Cell Biology
George A. Dominguez, Nicholas R. Anderson, Daniel A. Hammer
INTEGRATIVE BIOLOGY
(2015)
Meeting Abstract
Biophysics
George A. Dominguez, Daniel A. Hammer
BIOPHYSICAL JOURNAL
(2013)
Meeting Abstract
Oncology
George A. Dominguez, Kristen Maslar, Alexander Polo, Cyrus Sholevar, Anthony Campisi, John Roop, Dmitry Gabrilovich, Frank Rauscher, Amit Kumar
Article
Cell Biology
George A. Dominguez, Daniel A. Hammer
INTEGRATIVE BIOLOGY
(2014)
Article
Immunology
Sima Patel, Shuyu Fu, Jerome Mastio, George A. Dominguez, Abhilasha Purohit, Andrew Kossenkov, Cindy Lin, Kevin Alicea-Torres, Mohit Sehgal, Yulia Nefedova, Jie Zhou, Lucia R. Languino, Cynthia Clendenin, Robert H. Vonderheide, Charles Mulligan, Brian Nam, Neil Hockstein, Gregory Masters, Michael Guarino, Zachary T. Schug, Dario C. Altieri, Dmitry I. Gabrilovich
Article
Medicine, Research & Experimental
George A. Dominguez, Alexander T. Polo, John Roop, Anthony J. Campisi, Robert A. Somer, Adam D. Perzin, Dmitry Gabrilovich, Amit Kumar
BIOMARKER INSIGHTS
(2020)
Article
Medicine, Research & Experimental
Tatiana A. Karakasheva, George A. Dominguez, Ayumi Hashimoto, Eric W. Lin, Christopher Chiu, Kate Sasser, Jae W. Lee, Gregory L. Beatty, Dmitry I. Gabrilovich, Anil K. Rustgi
Article
Immunology
Thomas Condamine, George A. Dominguez, Je-In Youn, Andrew V. Kossenkov, Sridevi Mony, Kevin Alicea-Torres, Evgenii Tcyganov, Ayumi Hashimoto, Yulia Nefedova, Cindy Lin, Simona Partlova, Alfred Garfall, Dan T. Vogl, Xiaowei Xu, Stella C. Knight, George Malietzis, Gui Han Lee, Evgeniy Eruslanov, Steven M. Albelda, Xianwei Wang, Jawahar L. Mehta, Meenakshi Bewtra, Anil Rustgi, Neil Hockstein, Robert Witt, Gregory Masters, Brian Nam, Denis Smirnov, Manuel A. Sepulveda, Dmitry I. Gabrilovich
SCIENCE IMMUNOLOGY
(2016)